Literature DB >> 8413837

[3H]paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments.

S C Cheetham1, J A Viggers, N A Slater, D J Heal, W R Buckett.   

Abstract

Paroxetine is a selective and potent inhibitor of 5-hydroxytryptamine (5-HT) uptake into serotonergic neurones. [3H]Paroxetine binding to rat frontal cortex was of high affinity with a high percentage of specific binding. The binding data of both competition and saturation studies fitted a single site binding model. [3H]Paroxetine binding was potently inhibited by the selective 5-HT uptake inhibitors. In addition, a very good correlation was demonstrated between the ability of twenty-three compounds to inhibit [3H]paroxetine binding to rat frontal cortical membranes and [3H]5-HT uptake into rat frontal cortical synaptosomes. These data support the view that [3H]paroxetine binds to a single site which corresponds to the 5-HT uptake site. Using this ligand, the effects of repeated administration of antidepressant drugs with a wide range of pharmacological actions and electroconvulsive shock on 5-HT reuptake sites were examined. [3H]Paroxetine binding parameters (Kd and Bmax) were unaltered by all treatments. It would, therefore, appear that antidepressant therapy does not produce adaptive changes in 5-HT uptake sites.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8413837     DOI: 10.1016/0028-3908(93)90181-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  22 in total

1.  Preclinical characterization of WAY-211612: a dual 5-HT uptake inhibitor and 5-HT (1A) receptor antagonist and potential novel antidepressant.

Authors:  C E Beyer; Q Lin; B Platt; J Malberg; G Hornby; K M Sullivan; D L Smith; T Lock; P J Mitchell; N T Hatzenbuhler; D A Evrard; B L Harrison; R Magolda; M N Pangalos; L E Schechter; S Rosenzweig-Lipson; T H Andree
Journal:  Br J Pharmacol       Date:  2009-03-26       Impact factor: 8.739

2.  Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats.

Authors:  G Grignaschi; E Fanelli; I Scagnol; R Samanin
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

3.  Brain 5-hydroxytryptamine uptake sites labeled with [3H]paroxetine in antidepressant drug-treated depressed suicide victims and controls.

Authors:  K M Lawrence; F De Paermentier; S Lowther; M R Crompton; C L Katona; R W Horton
Journal:  J Psychiatry Neurosci       Date:  1997-05       Impact factor: 6.186

Review 4.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

5.  Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor.

Authors:  E P Pälvimäki; B L Roth; H Majasuo; A Laakso; M Kuoppamäki; E Syvälahti; J Hietala
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

6.  Thermogenic effects of sibutramine and its metabolites.

Authors:  I P Connoley; Y L Liu; I Frost; I P Reckless; D J Heal; M J Stock
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

7.  Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level.

Authors:  S Benmansour; M Cecchi; D A Morilak; G A Gerhardt; M A Javors; G G Gould; A Frazer
Journal:  J Neurosci       Date:  1999-12-01       Impact factor: 6.167

8.  Effects of sibutramine on the central dopaminergic system in rodents.

Authors:  T Nakagawa; K Ukai; T Ohyama; Y Gomita; H Okamura
Journal:  Neurotox Res       Date:  2001-07       Impact factor: 3.911

9.  Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats.

Authors:  Marisa B Rosenberg; F Ivy Carroll; S Stevens Negus
Journal:  J Pain       Date:  2013-01-16       Impact factor: 5.820

Review 10.  Sibutramine. A review of its contribution to the management of obesity.

Authors:  W McNeely; K L Goa
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.